🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

BRIEF-Aurinia completes licensing deal with Merck Animal Health

Published 2017-04-17, 04:28 p/m
© Reuters.  BRIEF-Aurinia completes licensing deal with Merck Animal Health
MRK
-
AUPH
-

April 17 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO -

* Aurinia completes licensing deal with Merck (NYSE:MRK) Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome

* Aurinia Pharma-signed agreement granting merck animal health worldwide rights to develop, commercialize co's nanomicellar voclosporin ophthalmic solution

* Aurinia Pharma-under deal, co will receive upfront payment, is eligible to receive further payments based on certain development and sales milestones

* Aurinia Pharmaceuticals Inc- under deal, aurinia will receive royalties based on global product sales

* Aurinia Pharma- under deal merck animal health to be responsible for remaining clinical development, commercialization of vos for use in animal health field

* Aurinia pharmaceuticals inc- under deal aurinia retains all human health rights related to vos Source text for Eikon: ID:nBw2FhTka Further company coverage: AUP.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.